- $13.36m
- $11.41m
- $25.66m
Annual income statement for Lifeward, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.39 | 5.97 | 5.51 | 13.9 | 25.7 |
| Cost of Revenue | |||||
| Gross Profit | 2.19 | 2.9 | 1.91 | 4.45 | 8.22 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 16.4 | 18.6 | 24.6 | 37.5 | 55 |
| Operating Profit | -12 | -12.7 | -19.1 | -23.6 | -29.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12.9 | -12.6 | -19.1 | -22.1 | -28.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13 | -12.7 | -19.6 | -22.1 | -28.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13 | -12.7 | -19.6 | -22.1 | -28.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13 | -12.7 | -19.6 | -22.1 | -28.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.76 | -1.86 | -2.2 | -2.54 | -2.59 |